DSpace Repository

Cost–effectiveness analysis of sacral neuromodulation (SNM) with Interstim* for fecal incontinence patients in Spain

Show simple item record

dc.contributor Universitat de Vic. Facultat d'Empresa i Comunicació
dc.contributor.author Brosa, Max
dc.contributor.author Muñoz Duyos, Arantxa
dc.contributor.author Navarro Luna, Albert
dc.contributor.author Rodriguez, José Manuel
dc.contributor.author Serrano, David
dc.contributor.author Gisbert, Ramon
dc.contributor.author Dziekan, Kristina
dc.contributor.author Segú, J.L.
dc.date.accessioned 2014-04-02T10:29:15Z
dc.date.available 2014-04-02T10:29:15Z
dc.date.created 2008
dc.date.issued 2008
dc.identifier.citation Brosa, M., Munoz-Duyos, A., Navarro-Luna, A., Rodriguez, J. M., Serrano, D., Gisbert Gelonch, R., . . . Segu, J. L. (2008). Cost-effectiveness analysis of sacral neuromodulation (SNM) with interstim for fecal incontinence patients in spain. Current Medical Research and Opinion; 4th Annual Meeting of Health Technology Assessment International, Barcelona, SPAIN. , 24(3) 907-918. ca_ES
dc.identifier.issn 0300-7995
dc.identifier.uri http://hdl.handle.net/10854/2826
dc.description.abstract Introduction: Fecal incontinence (FI) is a condition with a high impact on the psychological and social life of healthy people. Interstim, the sacral neuromodulation (SNM) therapy, has shown higher effectiveness and safety rates than surgical procedures like dynamic graciloplasty or artificial anal sphincter in patients with intact anal sphincter (IAS) and after sphincteroplasty in patients with structurally deficient anal sphincter (SDAS). Objective: To assess the cost-effectiveness of FI management in two scenarios – with and without SNM – and to estimate the potential budget impact of its progressive introduction in the Spanish setting. Methods: Two decision analytical models were developed (IAS and SDAS patients) representing the possible clinical paths for each of the scenarios (with and without SNM), as well as its clinical and economic consequences in the mid-to long term with a Markov model. Clinical and resource use data were retrieved from the literature and validated by a clinician expert panel. Effectiveness was measured with both QALYs and symptom-free years (SFY). A 3% discount rate was used for future costs and benefits (time horizon = 5 years). Prevalence figures were combined with Interstim sales forecasts to estimate the total number of patients to receive therapy over the next 5 years and the associated budget impact. Results: The introduction of Interstim in the therapeutic management of FI has an associated cost-effectiveness of €16 181 (IAS patients) and €22 195 (SDAS patients) per QALY gained. The progressive introduction of Interstim in 75 to 100 patients/year will have an estimated budget impact of 0.1% of incremental costs in patients with FI. Conclusions: Introducing Interstim in the management of FI in IAS and SDAS patients in the Spanish setting has shown to be an efficient measure with an incremental cost–effectiveness ratio below the accepted Spanish threshold (around €35 000/QALY), and with a relatively low additional cost for the Spanish NHS. ca_ES
dc.format application/pdf
dc.format.extent 12 p. ca_ES
dc.language.iso eng ca_ES
dc.publisher LIBRAPHARM LTD ca_ES
dc.rights © 2008 LibraPharm Limited
dc.rights Tots els drets reservats ca_ES
dc.subject.other Incontinència fecal -- Tractament ca_ES
dc.subject.other Cost de la malaltia ca_ES
dc.title Cost–effectiveness analysis of sacral neuromodulation (SNM) with Interstim* for fecal incontinence patients in Spain ca_ES
dc.type info:eu-repo/semantics/article ca_ES
dc.identifier.doi https://doi.org/10.1185/030079908X260970
dc.rights.accesRights info:eu-repo/semantics/closedAccess ca_ES
dc.type.version info:eu-repo/publishedVersion ca_ES
dc.indexacio Indexat a WOS/JCR ca_ES

Files in this item

Show simple item record

Search RIUVic